
|Articles|October 1, 2007
- Volume 0 0
Seven Deadly Sins AND HOW TO AVOID THEM: R?sum?
Advertisement
- SPELLING ERRORS?Proof, reproof, and have at least 2 reviewers proof your r?sum?.
- DIRTY/UNCLEAR PRINT?Print in traditional fonts with a size of at least 12 points, using a laser printer.
- POOR QUALITY PAPER?Purchase a high-grade, heavy bonded paper.
- WEAK CAREER OBJECTIVE?Write an objective that is ?employer-oriented? and not purely self-serving.
- NO COVER LETTER?Attach a cover letter that introduces you and your interest in the position.
- EXTRANEOUS MARKS, FOLDS, WRINKLES, TEARS?Keep your r?sum?s in a firm, closed folder.
- IMPERSONAL MAILING ADDRESS?Send your r?sum? to the individual who will make the hiring decision?not to thecompany or ?to whom it may concern.?
Articles in this issue
about 18 years ago
Seven Deadly Sins AND HOW TO AVOID THEM: Interviewsabout 18 years ago
PRUITT-SCHUTTE COMPETITION STRIVES FOR EXCELLENCEabout 18 years ago
DOCTOR TOM'S TOP TEN TIPS: PASSING THE PHARMACY BOARDSabout 18 years ago
PHARMACY GROUPS JOIN TOGETHER TO IMPROVE SERVICEabout 18 years ago
STUDENT POLITICAL INVOLVEMENT DOES IMPACT PHARMACYabout 18 years ago
OWNING YOUR OWN PHARMACY: A PLAN AND PARTNERSHIP COME TOGETHERabout 18 years ago
TECHNOLOGY EXPANDS PHARMACY REACH IN UNDERSERVED RURAL AREASabout 18 years ago
PARTNERSHIP PROGRAMS?A WIN-WIN FOR COMMUNITY PHARMACISTSabout 18 years ago
GOOD NEIGHBOR PHARMACY REWARDS EXCELLENCEabout 18 years ago
WELCOME TO INDEPENDENT PHARMACYNewsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
Updates in Treatment of Unresectable Hepatocellular Carcinoma
2
Soaring off the Patent Cliff: Preparing for the Next Wave of Oncology Biosimilars
3
Infliximab and Adalimumab Biosimilars Maintain Comparable Safety, Efficacy, Immunogenicity in IBD
4
Notable Updates in Medication Therapy Management in 2025
5











































































































































































































